Business Description
Mersana Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US59045L1061
Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.93 | |||||
| Equity-to-Asset | 0.01 | |||||
| Debt-to-Equity | 30.03 | |||||
| Debt-to-EBITDA | -0.46 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7.07 | |||||
| Beneish M-Score | -1.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 190 | |||||
| 3-Year EBITDA Growth Rate | -0.5 | |||||
| 3-Year EPS without NRI Growth Rate | 0.6 | |||||
| 3-Year FCF Growth Rate | -6.4 | |||||
| 3-Year Book Growth Rate | -54.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 18.98 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.5 | |||||
| 9-Day RSI | 31.73 | |||||
| 14-Day RSI | 36.34 | |||||
| 6-1 Month Momentum % | -7.69 | |||||
| 12-1 Month Momentum % | 0.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | |||||
| Quick Ratio | 2.35 | |||||
| Cash Ratio | 2.27 | |||||
| Days Sales Outstanding | 13.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.6 | |||||
| Shareholder Yield % | -1.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -228.07 | |||||
| Net Margin % | -214.2 | |||||
| FCF Margin % | -274.33 | |||||
| ROE % | -294.8 | |||||
| ROA % | -36.01 | |||||
| ROIC % | -167.35 | |||||
| ROC (Joel Greenblatt) % | -678.06 | |||||
| ROCE % | -48.7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.64 | |||||
| PB Ratio | 180 | |||||
| Price-to-Tangible-Book | 162 | |||||
| EV-to-EBIT | -0.93 | |||||
| EV-to-EBITDA | -0.95 | |||||
| EV-to-Revenue | 1.88 | |||||
| EV-to-Forward-Revenue | 45.18 | |||||
| EV-to-FCF | -0.68 | |||||
| Earnings Yield (Greenblatt) % | -107.53 | |||||
| FCF Yield % | -47.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRSN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mersana Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 34.837 | ||
| EPS (TTM) ($) | -0.61 | ||
| Beta | 0.36 | ||
| Volatility % | 110.46 | ||
| 14-Day RSI | 36.34 | ||
| 14-Day ATR ($) | 0.244373 | ||
| 20-Day SMA ($) | 2.1435 | ||
| 12-1 Month Momentum % | 0.99 | ||
| 52-Week Range ($) | 1.22 - 6.2801 | ||
| Shares Outstanding (Mil) | 123.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mersana Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mersana Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mersana Therapeutics Inc Frequently Asked Questions
What is Mersana Therapeutics Inc(MRSN)'s stock price today?
The current price of MRSN is $1.62. The 52 week high of MRSN is $6.28 and 52 week low is $1.22.
When is next earnings date of Mersana Therapeutics Inc(MRSN)?
The next earnings date of Mersana Therapeutics Inc(MRSN) is 2025-02-28 Est..
Does Mersana Therapeutics Inc(MRSN) pay dividends? If so, how much?
Mersana Therapeutics Inc(MRSN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers